Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CACNA1B | Q00975 | 7/20 | 0.45 |
| ▸ | CACNA1H | O95180 | 5/20 | 0.45 |
| ▸ | CCR4 | P51679 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | EDNRB | P24530 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21513762 | 1.00 | ALDH1A1 (0.48) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29968351 | 0.90 | CACNA1B (0.55) | ALDH1A1MEN1KMT2ACACNA1BCACNA1H | |
| SCHEMBL21512853 | 0.90 | CACNA1B (0.55) | ALDH1A1MEN1KMT2ACACNA1BCACNA1H | |
| SCHEMBL29970032 | 0.90 | CACNA1B (0.51) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21513746 | 0.89 | CACNA1B (0.48) | ALDH1A1SMN1; SMN2CACNA1BCACNA1HHTT | |
| SCHEMBL21513773 | 0.89 | CACNA1B (0.41) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29969100 | 0.89 | CACNA1B (0.41) | ALDH1A1MAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29969263 | 0.89 | CACNA1B (0.48) | ALDH1A1SMN1; SMN2CACNA1BCACNA1HHTT | |
| SCHEMBL21512821 | 0.89 | EDNRB (0.46) | ALDH1A1SMN1; SMN2CACNA1BCACNA1HHTT | |
| SCHEMBL29969350 | 0.89 | EDNRB (0.46) | ALDH1A1SMN1; SMN2CACNA1BCACNA1HHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | XRAD THERAPEUTICS, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4327877-A2 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRad Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3784671-B1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD THERAPEUTICS INC (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | XRAD HOLDING CAYMAN LIMITED (KY) | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315606-A1 | DUAL ATM AND DNA-PK INHIBITORS FOR USE IN ANTI-TUMOR THERAPY | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885MAPT 2006/4885SMN1; SMN2 2359/4885 |
| US-12187742-B2 | Dual ATM and DNA-PK inhibitors for use in anti-tumor therapy | ATM, CHEK2, CHEK1 | ALDH1A1 3354/4885MAPT 2006/4885SMN1; SMN2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.